Genetic, Biomarker, or Other Specimen Data
DNA is extracted from blood samples that are collected from Adult Changes in Thought (ACT) participants. Apolipoprotein E (APOE) genotype is routinely obtained from these samples and used in most ACT analyses. There are also plans to obtain new blood samples from participants at study visits. Data generated from these blood samples — including plasma biomarkers — will be part of the ACT Data Repository in the future.
Not applicable. Because these data elements are derived from the results of genetic and other biomarker tests, no forms are used to collect these data.
The following publications provide additional detail on the genetic and biomarker data elements. These may be helpful supporting citations when publishing analyses using these data.
- Crane PK, Trittschuh E, Mukherjee S, Saykin AJ, Sanders RE, Larson EB, McCurry SM, McCormick W, Bowen JD, Grabowski T, Moore M, Bauman J, Gross AL, Keene CD, Bird TD, Gibbons LE, Mez J; Executive Prominent Alzheimer's Disease: Genetics and Risk Factors (EPAD:GRF) Investigators. (2017). Incidence of cognitively defined late-onset Alzheimer's dementia subgroups from a prospective cohort study. Alzheimer's & Dementia, 13(12), 1307-1316. doi.org/10.1016/j.jalz.2017.04.011.
- Crane PK, Foroud T, Montine TJ, Larson EB. (2017). Alzheimer's Disease Sequencing Project discovery and replication criteria for cases and controls: Data from a community-based prospective cohort study with autopsy follow-up. Alzheimer's & Dementia, 13(12), 1410-1413. doi.org/10.1016/j.jalz.2017.09.010.